预约演示

Passage decides 26% of staff, 2 execs not needed on voyage deeper into clinic

2023-07-21

高管变更

Joining the Passage Bio chemistry, manufacturing and controls employees out the door will be Chief Financial Officer Simona King and Chief Technical Officer Alex Fotopoulos.

In a tricky Passage Biolimate, we’re increasingly used to hearing about biotechs reducing head count for their early-stage R&D work. But Passage Bio has decided to go in the other direction, laying off employees in its chemistry, manufacturing and controls (CMC) group to prioritize its development strategy.

The “organizational redesign” will see a 26% reduction in workforce, primarily among CMC employees—who are tasked with ensuring drug qualPassage Bioout the product development life cycle. As well as to extend the company’s resources, Passage said in a Securities and Exchange Commission filing that the intention is to “better align the biotech’s resources” with its R&D strategy.

Joining their CMC colleagues heading out the door will be Passage’s Chief Financial Officer Simona King and Chief Technical Officer Alex Fotopoulos, who are both set to leave the company next week. King had been in the CFO role less than two years, having joined the company at another period of significant upheaval for Passage's C-suite.

Kathleen Borthwick, who currently serves as vice president of finance at the company, will step up as interim CFO, Passage said.

Back in May, the central nervous system disorder-focused company was already highlighting its “steady focus” on its two lead clinical programs—PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia—both of which are set to produce interim data this year.

Safety and biomarcentral nervous system disorderof the phase 1/2 study in GM1 gangliosidosis, a genetic disorder that destroys nerve cells in tPBGM01in anGM1 gangliosidosis due PBFT02d outfrontotemporal dementiasets are due from the dementia trial by the end of the year.

Passage ended March with $167.8 million in cash and equivalents, which as GM1 gangliosidosispectgenetic disorderthe first half of 2025. The newly announced layoffs, combined with other “ongoing cash management initiatives,” mean the dementianow expects it will be able to fund its clinical programs through to the fourth quarter of 2025.

It’s not the first time the company has scaled back its workforce. In March 2022, Passage revealed plans to trim its head count by 13% as it prioritized R&D work deriving from a partnership with James Wilson, M.D., Ph.D, and his University of Pennsylvania lab.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构